Moderna, Inc. (BVMF:M1RN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 120.30B +111.3% |
| Revenue (ttm) | 11.54B -27.6% |
| Net Income | -16.32B |
| EPS | -41.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,084 |
| Open | 13.83 |
| Previous Close | 13.95 |
| Day's Range | 13.83 - 15.05 |
| 52-Week Range | 6.02 - 22.00 |
| Beta | 0.94 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
This new kind of flu shot by Moderna has just been approved by the FDA
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufactur...
Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal
Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Fo...
Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva
Moderna stock ($MRNA) fell 1.5% to $55.39 on Thursday despite getting big news from health regulators. The Food and Drug Administration approved Moderna’s new flu shot, mFlusiva, for adults 50…
Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future
Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market
Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market's sky-high expectations.
Moderna receives FDA approval for mFlusiva in adults 50 years, older
Moderna (MRNA) announced that the FDA has approved mFlusiva, a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from…
Moderna Stock (MRNA) Jumps on U.S. Approval for New Flu Shot Type — Why This Matters
Shares in Moderna ($MRNA) rose about 4% early Thursday after the pharma and biotech firm received the go-ahead from the U.S. health watchdog to sell a new type of flu…
FDA Approves First mRNA Flu Vaccine For Older Adults
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Modern...
The Food and Drug Administration approved Moderna's mRNA flu vaccine, the first of its kind, capping a review that nearly collapsed in February.
The decision caps a seven-month review that included a rare refusal to consider the shot at all.
US FDA approves first mRNA flu shot from Moderna
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for s...
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswir...
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Moderna announces initiation of Phase 1 trial of mRNA-1469
Moderna (MRNA) announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company’...
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and cu...
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collab...
Moderna price target raised to $60 from $41 at Citi
Citi raised the firm’s price target on Moderna (MRNA) to $60 from $41 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Moderna Wins a Post-COVID Earnings Beat as Analyst Eyes ‘Clinically Meaningful’ Trial Results
Moderna’s ($MRNA) latest earnings were better-than-expected. Jefferies ($JEF) analyst Andrew Tsai explained that while quarterly earnings beat expectations, new data from cancer treatments will show w...
Moderna Earnings Call Transcript: Q2 2026
Q2 2026 revenue exceeded guidance at $145 million, with improved cost discipline and a net loss of $782 million. Pipeline advanced with key regulatory milestones in flu and RSV vaccines, and oncology programs showed durable benefit. Revenue growth of up to 10% is expected for 2026.
Moderna Earnings release: Q2 2026
Moderna released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Moderna Slides: Q2 2026
Moderna has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
Moderna Quarterly report: Q2 2026
Moderna has published its Q2 2026 quarterly earnings report on July 31, 2026.
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Moderna sees FY26 cost of sales $1.7B, down from prior $1.8B view
The company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Moderna (MRNA) expects approximately 55%…